Editorial
-
Your Best Chance At Regulatory Compliance For Combination Products: Integrated Development
9/14/2023
The FDA now defines a prefilled syringe, a product that was at one point considered “packaging” for a drug, as a constituent part of a combination product. The ultimate combination of the drug, its package, and its delivery device means that during development and manufacturing you need to combine both drug and device current good manufacturing practices (cGMPs) and quality approaches.
-
Global Market Trends For Drug–Device Combination Products
9/12/2023
Drug–device combination products, also known simply as combination products, have a wide range of applications, including drug-eluting stents, prefilled syringes with medications, inhalers with drugs, transdermal patches with therapeutic agents, and more. This article shares new market research.
-
New ISO 14644-21:2023 Addresses Reducing Sampling Errors With Airborne Particle Counters
9/11/2023
The new ISO 14644 Part 21 addresses optimizing particle counter accuracy in cleanrooms, focusing on reducing sampling error and particle loss. Discussion includes the use of airborne particle counters, tubing, and isokinetic probes.
-
Survey Results Show What Could Finally Make Sustainability Stick
9/8/2023
Results from BioPlan's "20th Annual Report of Biopharmaceutical Manufacturing and Production" show that lasting sustainability strategies should focus on profitability aspects. That's because, even more than a spirit of stewardship, financial advantages provide a powerful incentive to stick to the plan.
-
Have You Adopted A Manufacturing Execution System Yet?
9/7/2023
Manufacturing execution systems (MES) have become crucial in managing bio/pharmaceutical operations to ensure compliance and promote efficiency. This article shares the benefits of adopting a MES, the three deployment options, manufacturing applications for MES, and more.
-
Effective Quality CDMO Contracting
9/6/2023
Choosing the right CDMO is a complex and difficult task and, given the regulatory framework within which the industry operates, it is essential that companies seeking a CDMO get the right partner. Let's look at what you should include in RFPs and other key considerations.
-
5 Best Practices For Responding To FDA Form 483 Inspection Observations
9/1/2023
How you respond to FDA Form 483 observations will determine if they escalate into more serious consequences, such as a warning letter or enforcement action. You don't want that. Follow this 5-step action plan to make sure the findings are properly addressed.
-
Efficient Biotech Vendor Selection And Management During Economic Uncertainty
8/30/2023
To navigate these turbulent economic waters effectively, we must view this funding crunch as a push for creativity and resiliency. This present moment requires a strategy integrating savvy financial management and strategic vendor selection to ensure a thriving biotech.
-
4 Ways To Gain A Competitive Edge In This Bio/Pharma Talent Shortage
8/25/2023
It’s no secret that finding pharma/biotech manufacturing talent is challenging, and the lack of workers is having a negative impact on productivity and growth. Here are four effective strategies for recruiting, training, educating, and retaining your workforce.
-
Vendor/Supplier Management To Maintain A Drug’s Safety Profile In End-To-End Supply Chain Planning
8/17/2023
FDA 21 CFR 211 requires vendor qualification as a part of the validation process and EU GxP requirements expect robust vendor management, and we expect regulators to issue firmer guidance sooner rather than later. Don't let your pharma/biotech fall short.